We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04116710
Recruitment Status : Completed
First Posted : October 7, 2019
Last Update Posted : August 29, 2022
Information provided by (Responsible Party):
Heat Biologics

Tracking Information
First Submitted Date  ICMJE October 3, 2019
First Posted Date  ICMJE October 7, 2019
Last Update Posted Date August 29, 2022
Actual Study Start Date  ICMJE October 18, 2019
Actual Primary Completion Date August 12, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 4, 2019)
  • Frequency of TEAEs, SAEs, and DLTs [ Time Frame: Up to 18 months ]
    Treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and dose-limiting toxicities (DLTs) will be assessed by CTCAE v5.0
  • To determine maximum tolerated dose and optimal immunological dose [ Time Frame: Up to 18 months ]
    The recommended phase 2 dose will be defined as an optimal immunological dose consisting of MTD as well as changes in immune markers in response to treatment.
Original Primary Outcome Measures  ICMJE
 (submitted: October 3, 2019)
  • Frequency of safety events [ Time Frame: Up to 18 months ]
    Frequency of treatment emergent adverse events (TEAEs), serious adverse events (SAEs) and dose-limiting toxicities (DLTs) assessed by CTCAE v5.0
  • To determine the recommended phase 2 dose (RP2D) of the combination HS-130 and HS-110 [ Time Frame: Up to 18 months ]
    The recommended phase 2 dose will be defined as an optimal immunological dose consisting of MTD as well as changes in immune markers in response to treatment.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: October 3, 2019)
  • Best Overall Response [ Time Frame: Up to 16 months ]
    Best Overall Response (BOR) as determined using RECIST v1.1.
  • Overall Survival [ Time Frame: Up to 18 months ]
    Overall Survival (OS) will be calculated as the duration from the date of first dose until the date of death from any cause, or is censored at date last known alive.
  • Progression-Free Survival [ Time Frame: Up to 18 months ]
    Progression-Free Survival (PFS) is defined as the duration from the date of first dose to the date of the first documented tumor progression (per RECIST v1.1) or death due to any cause.
  • Immunological effect [ Time Frame: Up to 18 months ]
    Immunological effect will be assessed by evaluating proportions of natural killer (NK) and T cell subsets for levels of activation, memory and exhaustion using flow cytometry
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors
Official Title  ICMJE A Phase I, First-in-human, Dose-escalation Study to Evaluate the Safety and Immunologic Response After Administration of HS-130 in Combination With HS-110 (Viagenpumatucel-L) in Patients With Solid Tumors Refractory to Standard Care
Brief Summary This is a phase 1 open-label, single center, dose escalation study to determine a safe and effective maximum tolerated dose of HS-130 in combination with viagenpumatucel-L (HS-110) for adult subjects with advanced solid tumors who are refractory to Standard of Care.
Detailed Description

This is an open-label, non-controlled, first-in-human Phase I study of HS-130 and HS-110 in patients with advanced solid tumors refractory to, or ineligible for, Standard of Care.

Seven dose levels will be explored in escalating doses. For each dose level, patients will receive combination HS-130 and HS-110 via intradermal injections once every 14 days. The Dose Limiting Toxicity (DLT) window of observation will include the first 28 days of treatment. In the absence of progressive disease or unacceptable toxicity, patients will continue to receive combination treatment every two weeks until disease progression, death, patient's withdrawal of consent, Investigator decision to discontinue treatment, or intolerable toxicity, whichever occurs first.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Advanced Solid Tumor
Intervention  ICMJE
  • Biological: HS-110 (viagenpumatucel-L)
    Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
  • Biological: HS-130
    Vaccine derived from irradiated human lung cancer cells expressing the co-stimulatory fusion protein OX40L-Ig
Study Arms  ICMJE Experimental: Phase 1: HS-130 + HS-110 (viagenpumatucel-L)
Patients will receive a combination of intradermal HS-130 and HS-110 once every 14 days. The dose levels will be determined by the starting dose and the escalation steps outlined in the protocol.
  • Biological: HS-110 (viagenpumatucel-L)
  • Biological: HS-130
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 22, 2021)
Original Estimated Enrollment  ICMJE
 (submitted: October 3, 2019)
Actual Study Completion Date  ICMJE April 1, 2022
Actual Primary Completion Date August 12, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Patients with metastatic or advanced, unresectable solid tumor who have progressed, or recurred following standard-of-care (SOC) therapies or are ineligible for safe and effective SOC therapies and for whom, in the opinion of the Investigator, experimental therapy with HS-130/HS-110 may be beneficial.
  2. Patients should have lesions that are safely accessible for biopsy and be willing to provide pre-treatment and on-treatment tissue biopsy. Fine-needle aspiration biopsy is not acceptable. Archival tumor tissue will be accepted in lieu of fresh biopsy at screening if sample was collected within 6-months from Cycle 1 Day 1, and the local pathologist confirms that an adequate amount of tissue/tumor cells exist to allow completion of all testing as outlined in the specimen collection manual.
  3. Age ≥ 18 years.
  4. Have an acceptable organ function:

    • Albumin ≥ 2.5 g/dL.
    • Total Bilirubin < 3.0 × upper limit of normal (ULN) unless patient has Gilbert's syndrome.
    • Alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 3.0 × ULN or ≤ 5 × ULN in the case of liver metastases.
    • Calculated or measured creatinine clearance > 35 mL/minute per the Cockcroft-Gault formula.
    • Absolute neutrophil count ≥ 1,500/mm3.
    • Hemoglobin ≥ 9 g/dL.
    • Platelet count ≥ 100,000/mm3.
  5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  6. Life expectancy of at least three months.
  7. Patients, both females and males, of childbearing/reproductive potential must agree to use adequate contraception while included in the trial and for six months after the last treatment with HS-130 and/or HS-110.
  8. Patients must be willing and have the capacity to sign the informed consent form.

Exclusion Criteria:

  1. Have clinically significant cardiac disease, including:

    • Onset of unstable angina within 6 months of signing the Informed Consent Form (ICF).
    • Acute myocardial infarction within 6 months of the signing the ICF.
    • Known congestive heart failure (Grade III or IV as classified by the New York Heart Association); and/ or a known decreased cardiac ejection fraction (LVEF) of < 45%.
    • Uncontrolled hypertension defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥ 100 mmHg, despite optimal medical management.
  2. Known or clinically suspected leptomeningeal disease. Stable, previously treated metastases in the brain or spinal cord, are allowed as long as these are considered stable (by CT or MRI), and not requiring systemic corticosteroids.
  3. History of ≥ grade 3 allergic reactions as well as known or suspected allergy or intolerance to any agent given in the course of this trial, live cell therapies, or live vaccines.
  4. History of suspected cytokine release syndrome (CRS).
  5. Known immunodeficiency disorders (testing not required).
  6. Ongoing or current autoimmune disease. Permanent but stable and manageable immune related adverse events (irAE) from prior therapies are permissible, if prednisone equivalent corticosteroid use does not exceed 10 mg/day.
  7. Any other condition requiring concurrent systemic immunosuppressive therapy (other than allowable exceptions which do not exceed 10mg/day of prednisone/corticosteroid use).
  8. Major surgery (requiring general anesthesia or inpatient hospitalization) within four weeks before first IMP administration.
  9. Any ongoing anticancer therapy including; small molecules, immunotherapy, chemotherapy, monoclonal antibodies or any other experimental drug. Prior therapy must be stopped within four weeks before first infusion in the study, or 5 half-lives, or twice the duration of the biological effect of the investigational product (whichever is shortest). Adjuvant anti-hormonal treatment(s) for previously treated breast cancer or prostate cancer are allowed. Bisphosphonates are allowed, Denosumab and other RANK ligand inhibitors are prohibited.
  10. Known current malignancy other than inclusion diagnosis. Prior curable cancer with complete remission for >2 years is allowed.
  11. Any other ongoing significant, uncontrolled medical condition as per Investigator discretion.
  12. Received a live vaccine within 30 days prior to first dose of study drug.
  13. Clinically significant active viral, bacterial or fungal infection requiring:

    1. Intravenous treatment with antimicrobial therapy completed less than two weeks prior to first dose, or
    2. Oral treatment with antimicrobial therapy completed less than one week prior to first dose.

    Prophylactic treatment with antibiotics (e.g. for dental extractions) is allowed.

  14. Known positive serology for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C (except in cases of immunity after cured infection). Testing not required.
  15. Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the trial or evaluation of the trial result in the opinion of the Investigator.
  16. Women who are pregnant or breast feeding.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT04116710
Other Study ID Numbers  ICMJE HS130-001
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party Heat Biologics
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Heat Biologics
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Rachel E. Sanborn, MD Providence Cancer Institute
PRS Account Heat Biologics
Verification Date February 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP